Weikang Pharmaceutical Co., Ltd.

Announcement on the Progress of Using Idle Funds for Entrusted Financial Management

Legal opinion letter for the 2025 Annual Shareholders' Meeting

Announcement of the resolution of the 2025 Annual Shareholders' Meeting

Announcement on the Pledge of Shares by Controlling Shareholders and Actual Controllers

Announcement on Participation in the 2026 Investor Online Collective Reception Day and 2025 Annual Performance Presentation of Listed Companies in Zhejiang

Announcement on the progress of using idle self-owned funds for entrusted wealth management

Announcement on the Progress of the Company's Transfer of Wholly-Owned Subsidiary Equity

Verification Opinion from Guolian Minsheng Securities Underwriting and Sponsorship Co., Ltd. on the Deposit and Use of Raised Funds for the Year 2025 by Zhejiang Weikang Pharmaceutical Co., Ltd.

Verification Opinion from Guolian Minsheng Securities Underwriting and Sponsorship Co., Ltd. on the Use of Part of the Overraised Funds to Permanently Supplement Working Capital by Zhejiang Weikang Pharmaceutical Co., Ltd.

Independent Director Work Report - Liu Jiangfeng

Independent Director Work Report - Hao Lan

Independent Director Work Report - Wu Bin

Internal Control Audit Report - Zhongtianheng Special Audit Document [2026] No. 0700

2025 Annual Internal Control Self-Evaluation Report

Announcement on Confirming the 2025 Compensation Distribution for the Company's Directors and Senior Executives and the 2026 Compensation Plan

Compensation Management System for Directors and Senior Management

Asset Valuation Report for the Fixed Assets, Construction in Progress, and Intangible Assets of Zhejiang Weikang Oujing Capsule Co., Ltd. Involved in the Goodwill Impairment Test Proposed by Zhejiang Weikang Pharmaceutical Co., Ltd.

Announcement on the Provision for Asset Impairment for the Year 2025

Asset Valuation Report for the Relevant Asset Group Including Goodwill Involved in the Goodwill Impairment Test Proposed by Zhejiang Weikang Pharmaceutical Co., Ltd. for the Merger with Zhejiang Weikang Oujing Capsule Co., Ltd.

Asset Valuation Report for the Preparation Asset Group Involved in the Goodwill Impairment Test Proposed by Zhejiang Weikang Pharmaceutical Co., Ltd.

Asset Valuation Report for the Modern Preparation Building Involved in the Goodwill Impairment Test Proposed by Zhejiang Weikang Pharmaceutical Co., Ltd.

Asset Valuation Report for the Herbal Medicine Asset Group Involved in the Goodwill Impairment Test Proposed by Zhejiang Weikang Pharmaceutical Co., Ltd.

Announcement on the Use of Part of the Overraised Funds to Permanently Supplement Working Capital

Announcement on Estimated Daily Related Transactions for the Year 2026

Notice of the 2025 Annual Shareholders' Meeting

Announcement on the Company's and Subsidiaries' Application for Credit Limits from Banks and Provision of Mortgage or Pledge Guarantees for the Year 2026

Announcement of Resolutions from the 11th Meeting of the 4th Board of Directors

2025 Annual Financial Settlement Report

2025 Annual Board Work Report

Goodwill Impairment Test Report

Announcement on the Proposal Not to Distribute Profits for the Year 2025

2026 First Quarter Report

Special Report on the Deposit and Use of Raised Funds for the Year 2025

Review Report on the Special Explanation Regarding the Elimination of Matters Related to the Non-Standard Audit Opinion in the 2024 Annual Audit Report - Zhongtianheng Special Audit Document [2026] No. 1123

Opinion of the Audit Committee on the Special Explanation from the Board Regarding the Elimination of Matters Related to the Non-Standard Audit Opinion in the 2024 Annual Audit Report

Special Explanation from the Board Regarding the Elimination of Matters Related to the Non-Standard Audit Opinion in the 2024 Annual Audit Report

Verification Report on the Annual Deposit and Actual Use of Raised Funds - Zhongtianheng Special Audit Document [2026] No. 1018

Special Verification Opinion on the 2025 Annual Operating Revenue Deduction Table - Zhongtianheng Special Audit Document [2026] No. 1017

Report of the Board Audit Committee on the Evaluation of the Performance of the Accounting Firm for the Year 2025 and the Fulfillment of Supervision Responsibilities

Special Audit Opinion on the Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions - Zhongtianheng Special Audit Document [2026] No. 1016

2025 Annual Non-Operating Fund Occupation and Other Related Fund Transactions Table

Special Report on the Self-Examination of Independent Directors' Independence

2025 Annual Audit Report

2025 Annual Report

Summary of the 2025 Annual Report

Announcement on Using Idle Self-owned Funds for Entrusted Wealth Management

Announcement on Redemption of Entrusted Wealth Management Using Idle Own Funds

Announcement on Share Pledge by Shareholders Holding 5% or More of Shares